Clinical Trial: ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naive/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07551544) titled 'ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naive/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer' on April 20.

Brief Summary: This is an open-label, randomized, phase 3 study of intravesical BCG plus ANKTIVA (experimental arm) versus BCG alone (control arm) in participants who have histologically confirmed, BCG-naive/BCG-exposed high-grade Ta/T1 papillary disease. The purpose of this study is to evaluate the contribution of effect of neoadjuvant ANKTIVA plus BCG experimental therapy in papillary NMIBC.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: NMIBC

Intervention: ...